In the repair of complex congenital heart defects or in surgery of the aortic arch, normal circulation may be temporarily halted to ensure a clean bloodless operation field. The brain is the organ most vulnerable to ischemic injury during this period of hypothermic circulatory arrest (HCA), and the mortality and morbidity of these procedures today consists largely of neurological complications. Ischemic preconditioning, a plausible neuroprotective strategy, describes a concept whereby brief exposure to ischemia, in a dose below the threshold for tissue injury, provides robust protection against the injurious effects of a subsequent more severe insult. In remote ischemic preconditioning, intermittent ischemia is induced in a nontarget tissue such as the limb, and the signal is thought to spread systemically by a mechanism that includes activation of the autonomic nervous system and as yet unidentified humoral mediators. Our study demonstrates that the neuroprotective effect after a series of blood pressure cuff inflations of the hind leg before HCA in a surviving porcine model was associated with a significant reduction in some important markers of neurological injury, accelerated neurological recovery and mitigated cerebral histopathological findings. Remote ischemic preconditioning might be neuroprotective in patients undergoing surgery with HCA and improve long-term outcomes. If intermittent limb occlusions are shown consistently to reduce neurological injury during complex cardiac surgery with HCA, clinical implications can be very important. The intervention is practical, cost effective, and noninvasive. Clinical trials to further investigate its applications are warranted. See p 714.
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial
In the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial, routine early eptifibatide before angiography was not superior to delayed provisional use during percutaneous coronary intervention but led to more bleeding. The efficacy and safety of early eptifibatide in the setting of upstream clopidogrel use is unknown. In this study of 9166 non-ST-segment elevation acute coronary syndrome patients who underwent coronary angiography in the EARLY ACS trial, we found that early preprocedure use of eptifibatide did not improve short-term ischemic outcomes but may be associated with a reduction in 30-day ischemic risk after upstream treatment with clopidogrel. The addition of clopidogrel accentuated bleeding risks associated with early eptifibatide use. These findings lend support to the concept of enhanced value for additive antiplatelet therapies, and future investigations are needed to identify those patients who may benefit from more intensive platelet inhibition without a significant excess in bleeding risk. See p 722.
Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels
C-reactive protein (CRP) is a heritable marker of chronic inflammation that is strongly associated with cardiovascular disease. Although environmental factors such as obesity, smoking, and hormone therapy influence levels of serum CRP, genes play an important role in determining serum CRP levels. The advent of genome-wide association studies has provided an opportunity to identify previously unsuspected genetic loci that influence complex traits. In this study, we collected data on Ͼ80 000 subjects from 25 studies and identified 18 genetic loci that are associated with serum CRP levels. These genetic loci provide valuable insights into the pathways that affect serum levels of CRP. Although further investigations are needed to understand the exact mechanisms, our findings highlight immune response and metabolic regulatory pathways involved in the regulation of chronic inflammation, as well as several loci previously unknown to be related to inflammation. However, these single-nucleotide polymorphisms were not associated with incident myocardial infarction or coronary heart disease, either individually or in combination. A better knowledge of the molecular mechanisms that control serum CRP levels may lead to a deeper understanding of the complex interactions underlying the inflammatory response in cardiovascular disease. See p 731.
IScore: A Risk Score to Predict Death Early After Hospitalization for an Acute Ischemic Stroke
Stroke is a leading cause of death and adult disability. The ability to estimate prognosis in acute stroke patients directly affects treatment decisions for patients. It may also guide supportive care plan and facilitate patient and/or family counseling or discussions pertaining to end-of-life decisions. At the population level, prognostic estimations may assist policymakers in conducting fair comparisons when evaluating stroke fatality among different facilities for hospital outcomes and performance assessment. Clinicians usually rely on their own personal experience or average mortality reported in clinical trials, which do not account for valuable information available at the time of the hospital presentation. Unfortunately, few risk scores are available that include simple and relevant clinical variables, including stroke severity on admission. In this large cohort study, we created and validated a risk score model to predict 30-day and 1-year mortality early after hospitalization for patients with an acute ischemic stroke. Our model was designed to include clinical variables easily obtained in the early hours of hospital presentation and is independent of specialized laboratory tests or imaging evaluations. Additionally, this model allows estimating death at small centers and at community hospitals with limited resources. Predictors of mortality included older age, male sex, severe stroke, nonlacunar stroke subtype, glucose Ն7.5 mmol/L (135 mg/dL), history of atrial fibrillation, coronary artery disease, congestive heart failure, cancer, kidney disease on dialysis, and dependency before the stroke. Our risk score helps to estimate 30-day and 1-year mortality in individuals presenting with an acute ischemic stroke. Examples are provided in the text. An online Web-based tool (http://www.sorcan.ca/iscore) is available to estimate mortality by adding individual patient characteristics. See p 739.
Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes
Tissue-type plasminogen activator (tPA) is a proven intervention for acute ischemic stroke patients. The benefits of intravenous tPA in acute ischemic stroke are time dependent, and guidelines recommend an arrival to treatment initiation (door-to-needle) time of Յ60 minutes. Despite the proven benefits, guidelines recommendations, and explicit goals for timely administration of tPA, the frequency, patient and hospital characteristics, temporal trends, and outcomes of ischemic stroke with door-to-needle times Յ60 minutes have not been well studied. Data from 25 504 acute ischemic stroke patients treated with tPA within 3 hours of symptom onset from 2003 to 2009 in 1082 hospitals participating in the Get With the Guidelines-Stroke Program were analyzed to determine frequency, patient and hospital characteristics, and temporal trends in patients treated with door-toneedle times Յ60 minutes. Only 26.6% of tPA-treated patients had a door-to-needle time Յ60 minutes. Patient factors most strongly associated with door-to-needle time Յ60 minutes were younger age, male gender, white race, and no prior stroke. Hospital factors associated with Յ60-minute door-to-needle times included greater annual volumes of tPA-treated stroke patients. The proportion of patients with door-to-needle times Յ60 minutes varied widely by hospital and increased modestly from 19.5% in 2003 to 29.1% in 2009. Despite similar stroke severity, in-hospital mortality was lower and symptomatic intracranial hemorrhage was less frequent for patients with door-to-needle times Յ60 minutes compared with patients with door-to-needle times Ͼ60 minutes. These findings support the need for a targeted initiative to improve the timeliness of reperfusion in acute ischemic stroke. See p 750.
Listing and Transplanting Adults With Congenital Heart Disease
An increasing number of patients with congenital heart disease (CHD) are reaching adulthood. These patients, often with systemic right ventricles or long-standing valvular disease, are at increased risk for the development of heart failure and may require heart transplantation. These adult patients with CHD may need to be managed differently from non-CHD patients, but few studies have specifically examined their outcomes both on the waiting list and after transplantation. A better understanding of the differences between CHD and non-CHD patients may enable improvements in the outcomes of this increasingly important population. In this study, we demonstrate that patients with CHD are different from those without CHD: They are younger and have fewer comorbidities but have higher early posttransplantation mortality. Mechanical circulatory assistance is not associated with improved survival among CHD patients on the waiting list. The increasingly common transplantation of patients with complex CHD may result in particularly high posttransplantation mortality, and centers performing these transplantations should proceed with caution. Collection of data specific to the CHD population, including accurate congenital diagnoses, is essential to better understanding and improving the outcomes with transplantation in this population. See p 759.
